Foghorn Therapeutics (FHTX) to Announce Earnings on Tuesday

Foghorn Therapeutics (NASDAQ:FHTX) will likely be releasing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect Foghorn Therapeutics to post earnings of ($0.23) per share and revenue of $6.8050 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 6, 2026 at 9:30 AM ET.

Foghorn Therapeutics (NASDAQ:FHTX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.01). The company had revenue of $3.27 million during the quarter, compared to analysts’ expectations of $7.94 million. On average, analysts expect Foghorn Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Foghorn Therapeutics Trading Down 4.4%

Shares of NASDAQ:FHTX opened at $4.53 on Friday. Foghorn Therapeutics has a 1-year low of $3.27 and a 1-year high of $6.95. The stock has a market capitalization of $265.96 million, a P/E ratio of -3.91 and a beta of 2.86. The business has a 50-day moving average price of $4.64 and a two-hundred day moving average price of $5.01.

Institutional Trading of Foghorn Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of FHTX. Russell Investments Group Ltd. boosted its stake in Foghorn Therapeutics by 13,755.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,542 shares of the company’s stock worth $27,000 after acquiring an additional 5,502 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Foghorn Therapeutics by 48.0% in the third quarter. BNP Paribas Financial Markets now owns 7,103 shares of the company’s stock worth $35,000 after purchasing an additional 2,305 shares during the period. Tower Research Capital LLC TRC raised its holdings in Foghorn Therapeutics by 136.8% in the second quarter. Tower Research Capital LLC TRC now owns 9,213 shares of the company’s stock worth $43,000 after purchasing an additional 5,323 shares during the period. Invesco Ltd. bought a new position in shares of Foghorn Therapeutics during the fourth quarter worth $58,000. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Foghorn Therapeutics in the 3rd quarter valued at $58,000. 61.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on FHTX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Foghorn Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of Foghorn Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.43.

About Foghorn Therapeutics

Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.

The company’s lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.